The College of Nuclear Physicians of South Africa practice guidelines on peptide receptor radionuclide therapy in neuroendocrine tumours

Simple item page
dc.contributor.authorLawal, I.en_ZA
dc.contributor.authorLouw, L.en_ZA
dc.contributor.authorWarwick, James M.en_ZA
dc.contributor.authorNyakale, N.en_ZA
dc.contributor.authorSteyn, R.en_ZA
dc.contributor.authorLengana, T.en_ZA
dc.contributor.authorEllmann, A.en_ZA
dc.contributor.authorKotze, Ten_ZA
dc.contributor.authorVangu, M.en_ZA
dc.contributor.authorVorster, M.en_ZA
dc.contributor.authorSathekge, M.en_ZA
dc.date.accessioned2020-03-04T13:43:25Z
dc.date.available2020-03-04T13:43:25Z
dc.date.issued2018
dc.descriptionCITATION: Lawal, I., et al. 2018. The College of Nuclear Physicians of South Africa Practice Guidelines on peptide receptor radionuclide therapy in neuroendocrine tumours. South African Journal of Surgery, 56(3):55-64, doi:10.17159/2078-5151/2018/v56n3a2775.
dc.descriptionThe original publication is available at http://www.scielo.org.za
dc.description.abstractBackground: Peptide receptor radionuclide therapy (PRRT) for metastatic or inoperable neuroendocrine tumours (NETs) is a systemic therapy which targets somatostatin receptors overexpressed by differentiated NETs for endoradiotherapy. This guideline has been compiled by the College of Nuclear Physicians of the Colleges of Medicine of South Africa, with endorsement by the South African Society of Nuclear Medicine and the Association of Nuclear Physicians to guide Nuclear Medicine Physicians in its application during the management of these patients. Recommendations: Patients with well- to moderately-differentiated NETs should be comprehensively worked-up to determine their suitability for PRRT. Treatment should be administered by a Nuclear Medicine Physician in a licensed, appropriately equipped and fully staffed facility. Patient monitoring is mandatory during and after each therapy cycle to identify and treat therapy-related adverse events. Patients should also be followed-up after completion of therapy cycles for monitoring of long-term toxicities and response assessment. Conclusion: PRRT is a safe and effective therapy option in patients with differentiated NETs. Its use in appropriate patients is associated with a survival benefit.en_ZA
dc.description.urihttp://www.scielo.org.za/scielo.php?script=sci_abstract&pid=S0038-23612018000300011&lng=en&nrm=iso
dc.description.versionPublishers version
dc.format.extent9 pages
dc.identifier.citationLawal, I., et al. 2018. The College of Nuclear Physicians of South Africa Practice Guidelines on peptide receptor radionuclide therapy in neuroendocrine tumours. South African Journal of Surgery, 56(3):55-64, doi:10.17159/2078-5151/2018/v56n3a2775
dc.identifier.issn2078-5151 (online)
dc.identifier.issn0038-2361 (print)
dc.identifier.otherdoi:10.17159/2078-5151/2018/v56n3a2775
dc.identifier.urihttp://hdl.handle.net/10019.1/107581
dc.language.isoen_ZAen_ZA
dc.publisherHealth and Medical Publishing Group
dc.rights.holderAuthors retain copyright
dc.subjectPeptide receptor radionuclide therapy -- Practice -- South Africaen_ZA
dc.subjectMedical protocols -- South Africaen_ZA
dc.subjectTumors -- Radiotherapy -- Practice -- South Africaen_ZA
dc.subjectMetastasis -- Radiotherapy -- Practice -- South Africaen_ZA
dc.subjectRadiopharmaceuticals -- Practice -- South Africaen_ZA
dc.titleThe College of Nuclear Physicians of South Africa practice guidelines on peptide receptor radionuclide therapy in neuroendocrine tumoursen_ZA
dc.typeArticleen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
lawal_college_2018.pdf
Size:
318.93 KB
Format:
Adobe Portable Document Format
Description:
Download article
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Research Articles (Nuclear Medicine)